Skip to main content
. 2019 Jun 26;11(7):896. doi: 10.3390/cancers11070896

Figure 1.

Figure 1

(A) Progression-free-survival (PFS) in patients with +12 chronic lymphocytic leukemia (CLL) vs. fluorescence in situ hybridization (FISH) negative CLL; (B) treatment-free-survival (TFS) in patients with +12 CLL vs. FISH negative CLL; (C) overall survival (OS) in patients with +12 CLL vs. FISH negative CLL.